KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Retained Earnings: 2020-2024

Historic Retained Earnings for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $116.9 million.

  • AbCellera Biologics' Retained Earnings fell 113.59% to -$20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.5 million, marking a year-over-year decrease of 113.59%. This contributed to the annual value of $116.9 million for FY2024, which is 58.21% down from last year.
  • As of FY2024, AbCellera Biologics' Retained Earnings stood at $116.9 million, which was down 58.21% from $279.8 million recorded in FY2023.
  • Over the past 5 years, AbCellera Biologics' Retained Earnings peaked at $426.2 million during FY2022, and registered a low of $114.2 million during FY2020.
  • Over the past 3 years, AbCellera Biologics' median Retained Earnings value was $279.8 million (recorded in 2023), while the average stood at $274.3 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first skyrocketed by 134.38% in 2021, then plummeted by 58.21% in 2024.
  • Over the past 5 years, AbCellera Biologics' Retained Earnings (Yearly) stood at $114.2 million in 2020, then skyrocketed by 134.38% to $267.7 million in 2021, then soared by 59.22% to $426.2 million in 2022, then tumbled by 34.35% to $279.8 million in 2023, then slumped by 58.21% to $116.9 million in 2024.